Feasibility study of Epirubicin-Eluting-Bead Embolization for Hepatocellular Carcinoma (JIVROSG-1301) - Feasibility study of DEB-epiDOX for HCC (JIVROSG-1301)

Japan Interventional Radiology In Oncology Study Group(IVROSG)0 个研究点目标入组 8 人开始时间: 2014年4月23日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Prior surgical reconstruction or endoscopic treatment of the biliary tract 2) Clinically significant refractory ascites or pleural effusion 3) Severe arterio-portal or arterio-venous shunts in the liver 4) Allergy to contrast medium that precludes angiography 5) Severe, active co-morbidity, defined as follows: - Uncontrolled cardiac failure, angina and/or rhythm disorders - Myocardial infarction within the last 6 months - Renal failure - Active infection (viral hepatitis is allowed) - Active gastrointestinal bleeding - Other active malignant tumor - Hepatic encephalopathy or severe mental disorder 6) Pregnancy, nursing women, or women of childbearing potential, and men who are sexually active and not willing or able to use medically acceptable forms of contraception 7) Not eligible because of safety issues judged by investigators

发起方

Japan Interventional Radiology In Oncology Study Group(IVROSG)